Chinese Journal of Blood Purification ›› 2024, Vol. 23 ›› Issue (07): 534-537.doi: 10.3969/j.issn.1671-4091.2024.07.010

Previous Articles     Next Articles

Research progresses in blood perfusion joint continuous renal replacement therapy in rhabdomyolysis-induced acute kidney injury

ZHOU Xiao-chun, YANG Ying-ying, FU Ping   

  1. Department of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu 610041, China; 2Department of Nephrology, Guanghan Hospital of Traditional Chinese Medicine, Deyang 618300, China
  • Received:2024-03-22 Revised:2024-04-15 Online:2024-07-12 Published:2024-07-12
  • Contact: 610041 成都,1四川大学华西医院肾脏内科/四川大学华西肾脏病研究所 E-mail:fupinghx@scu.edu.cn

Abstract: Rhabdomyolysis (RM) is a multifactorial clinical syndrome of skeletal muscle injury and release of its breakdown products into the circulation. Acute kidney injury (AKI) is a common complication of RM, which is mainly related to myoglobin occlusion of renal tubules and its direct nephrotoxic effects, and others. RM-induced AKI has a low cure rate and high mortality. Previous studies have shown that continuous renal replacement therapy (CRRT) combined with hemoperfusion (HP) can be effective in treating RM-induced AKI. This article provides a review of CRRT combined with HP in the treatment of RM-induced AKI with the aim to provide a reference for clinical therapeutic decision-making and possible follow-up studies.

Key words: Rhabdomyolysis, Acute kidney injury, Myoglobin;Continuous renal replacement therapy, Hemoperfusion

CLC Number: